GSK 576389A

Drug Profile

GSK 576389A

Alternative Names: FluAS25 adjuvanted influenza vaccine - GlaxoSmithKline; FluAS25 adjuvanted inluenza vaccine - GlaxoSmithKline; GSK576389A; Seasonal influenza virus vaccine - GlaxoSmithKline

Latest Information Update: 14 Feb 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Influenza virus infections

Most Recent Events

  • 01 Jan 2011 Discontinued prior to 2011 - Phase-III for Influenza virus infections (prevention in the elderly) in USA, Germany and Norway (IM)
  • 01 Jan 2011 Discontinued prior to 2011- Phase-II for Influenza virus infections (prevention in the elderly) in Denmark, Belgium, Netherlands, Estonia, United Kingdom and Sweden (IM)
  • 01 Oct 2007 Phase-II clinical trials in Influenza virus infections (prevention in the elderly) in Belgium, United Kingdom, Germany, Netherlands and Sweden (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top